164 related articles for article (PubMed ID: 17513019)
21. A QSAR study on influenza neuraminidase inhibitors.
Verma RP; Hansch C
Bioorg Med Chem; 2006 Feb; 14(4):982-96. PubMed ID: 16213733
[TBL] [Abstract][Full Text] [Related]
22. Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors.
Zhang J; Pan X; Wang C; Wang F; Li P; Xu W; He L
Chem Biol Drug Des; 2012 Mar; 79(3):353-9. PubMed ID: 22222003
[TBL] [Abstract][Full Text] [Related]
23. Rational design and 3D-pharmacophore mapping of 5'-thiourea-substituted alpha-thymidine analogues as mycobacterial TMPK inhibitors.
Andrade CH; Pasqualoto KF; Ferreira EI; Hopfinger AJ
J Chem Inf Model; 2009 Apr; 49(4):1070-8. PubMed ID: 19296716
[TBL] [Abstract][Full Text] [Related]
24. Quantitative structure activity relationship of benzoxazinone derivatives as neuropeptide Y Y5 receptor antagonists.
Deswal S; Roy N
Eur J Med Chem; 2006 Apr; 41(4):552-7. PubMed ID: 16545499
[TBL] [Abstract][Full Text] [Related]
25. Combining docking, scoring and molecular field analyses to probe influenza neuraminidase-ligand interactions.
Abu Hammad AM; Afifi FU; Taha MO
J Mol Graph Model; 2007 Sep; 26(2):443-56. PubMed ID: 17360207
[TBL] [Abstract][Full Text] [Related]
26. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Mitrasinovic PM
Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
[TBL] [Abstract][Full Text] [Related]
27. [Function of neuraminidase of influenza virus and anti influenza compounds by its inhibition].
Yamashita M
Tanpakushitsu Kakusan Koso; 2009 Aug; 54(10):1284-91. PubMed ID: 19663256
[No Abstract] [Full Text] [Related]
28. Anti-influenza drugs: the development of sialidase inhibitors.
von Itzstein M; Thomson R
Handb Exp Pharmacol; 2009; (189):111-54. PubMed ID: 19048199
[TBL] [Abstract][Full Text] [Related]
29. Influenza virus neuraminidase: structure, antibodies, and inhibitors.
Colman PM
Protein Sci; 1994 Oct; 3(10):1687-96. PubMed ID: 7849585
[TBL] [Abstract][Full Text] [Related]
30. Quantitative structure-activity relationship studies on 2-amino-6-arylsulfonylbenzonitriles as human immunodeficiency viruses type 1 reverse transcriptase inhibitors using descriptors obtained from substituents and whole molecular structures.
Hemmateenejad B; Sabet R; Fassihi A
Chem Biol Drug Des; 2009 Oct; 74(4):405-15. PubMed ID: 19691465
[TBL] [Abstract][Full Text] [Related]
31. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
32. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
33. Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).
Du QS; Huang RB; Wei YT; Du LQ; Chou KC
J Comput Chem; 2008 Jan; 29(2):211-9. PubMed ID: 17559075
[TBL] [Abstract][Full Text] [Related]
34. Study on molecular mechanism and 3D-QSAR of influenza neuraminidase inhibitors.
Yi X; Guo Z; Chu FM
Bioorg Med Chem; 2003 Apr; 11(7):1465-74. PubMed ID: 12628672
[TBL] [Abstract][Full Text] [Related]
35. QSAR study of PETT derivatives as potent HIV-1 reverse transcriptase inhibitors.
Sabet R; Fassihi A; Moeinifard B
J Mol Graph Model; 2009 Sep; 28(2):146-55. PubMed ID: 19570701
[TBL] [Abstract][Full Text] [Related]
36. Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors.
Roy K; Roy PP
Chem Biol Drug Des; 2008 Nov; 72(5):370-82. PubMed ID: 19012573
[TBL] [Abstract][Full Text] [Related]
37. Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target.
Hochgürtel M; Biesinger R; Kroth H; Piecha D; Hofmann MW; Krause S; Schaaf O; Nicolau C; Eliseev AV
J Med Chem; 2003 Jan; 46(3):356-8. PubMed ID: 12540234
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
Liu AL; Wang HD; Lee SM; Wang YT; Du GH
Bioorg Med Chem; 2008 Aug; 16(15):7141-7. PubMed ID: 18640042
[TBL] [Abstract][Full Text] [Related]
39. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.
Du QS; Huang RB; Wei YT; Pang ZW; Du LQ; Chou KC
J Comput Chem; 2009 Jan; 30(2):295-304. PubMed ID: 18613071
[TBL] [Abstract][Full Text] [Related]
40. QSAR study of heparanase inhibitors activity using artificial neural networks and Levenberg-Marquardt algorithm.
Jalali-Heravi M; Asadollahi-Baboli M; Shahbazikhah P
Eur J Med Chem; 2008 Mar; 43(3):548-56. PubMed ID: 17602800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
